Search results
Results from the WOW.Com Content Network
(Reuters) -Moderna said on Friday the European Patent Office had upheld the validity of one of the company's key patents, a win in an ongoing COVID-19 vaccine dispute with Pfizer and BioNTech.
Biotech firm Promosome LLC sued Moderna, Pfizer and BioNTech in federal court in San Diego, California, on Tuesday, accusing their COVID-19 vaccines of infringing a patent related to messenger RNA ...
LONDON (Reuters) -Pfizer and Moderna's legal battle over their rival COVID-19 vaccines looks set to continue after London's High Court gave a mixed ruling on two of Moderna's patents, likely ...
In December 2018, Moderna became a public company via the largest initial public offering of a biotechnology company in history, raising $621 million by selling 27 million shares at $23 per share. [25] [26] The first mRNA vaccine developed by Moderna was for influenza in 2015, and its first antibody encoded by mRNA was in 2019. [6]
The Moderna news followed preliminary results from the Pfizer-BioNTech vaccine candidate, BNT162b2, with Moderna demonstrating similar efficacy, but requiring storage at the temperature of a standard medical refrigerator of 2–8 °C (36–46 °F) for up to thirty days or −20 °C (−4 °F) for up to four months, whereas the Pfizer-BioNTech ...
Pfizer, BioNTech and biotech firm Promosome told a federal judge in San Diego, California that they have agreed to end Promosome's lawsuit accusing the COVID-19 vaccine makers of infringing a ...
A class action lawsuit was filed in August 2020 against Vaxart in Northern California U.S. District Court for alleged securities fraud, [94] a concern related to Vaxart executives enriching themselves by selling shares timed to positive news on vaccine development during mid-2020. [95]
For premium support please call: 800-290-4726 more ways to reach us